Discovery and characterization of olokizumab

References

• Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122:143 - 59; http://dx.doi.org/10.1042/CS20110340; PMID: 22029668
   PubMed Web of Science ®Google Scholar
• Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4:Suppl 3 S233 - 42; http://dx.doi.org/10.1186/ar565; PMID: 12110143
   PubMedGoogle Scholar
• Assier E, Boissier M-C, Dayer J-M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010; 77:532 - 6; http://dx.doi.org/10.1016/j.jbspin.2010.07.007; PMID: 20869898
   PubMed Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375 - 83; http://dx.doi.org/10.1172/JCI57158; PMID: 21881215
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813:878 - 88; http://dx.doi.org/10.1016/j.bbamcr.2011.01.034; PMID: 21296109
   PubMed Web of Science ®Google Scholar
• Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300:2101 - 4; http://dx.doi.org/10.1126/science.1083901; PMID: 12829785
   PubMed Web of Science ®Google Scholar
• Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J 1997; 16:989 - 97; http://dx.doi.org/10.1093/emboj/16.5.989; PMID: 9118960
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8:1237 - 47; http://dx.doi.org/10.7150/ijbs.4989; PMID: 23136552
   PubMed Web of Science ®Google Scholar
• Veverka V, Baker T, Redpath N, Carrington B, Muskett F, Taylor R, et al. Conservation of functional sites on interleukin-6 and implications for evolution of signalling complex assembly. J Biol Chem 2012; 287:40043 - 50; http://dx.doi.org/10.1074/jbc.M112.405597; PMID: 23027872
   PubMed Web of Science ®Google Scholar
• Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49:15 - 24; http://dx.doi.org/10.1093/rheumatology/kep329; PMID: 19854855
   PubMed Web of Science ®Google Scholar
• Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004; 63:233 - 9; http://dx.doi.org/10.1136/ard.2003.013276; PMID: 14962955
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012; 2012:946048; http://dx.doi.org/10.1155/2012/946048; PMID: 22315615
   PubMedGoogle Scholar
• Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 1992; 102:514 - 9; PMID: 1370661
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542 - 52; http://dx.doi.org/10.1002/art.27221; PMID: 20112381
   PubMed Web of Science ®Google Scholar
• Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011:432595; http://dx.doi.org/10.1155/2011/432595; PMID: 22028588
   PubMed Web of Science ®Google Scholar
• Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008; 47:1635 - 40; http://dx.doi.org/10.1093/rheumatology/ken363; PMID: 18786965
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390 - 407; http://dx.doi.org/10.1038/ncpgasthep0528; PMID: 16819502
   PubMedGoogle Scholar
• Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36:45 - 9; http://dx.doi.org/10.1136/gut.36.1.45; PMID: 7890234
   PubMed Web of Science ®Google Scholar
• Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13:339 - 43; http://dx.doi.org/10.1191/0961203304lu1023oa; PMID: 15230289
   PubMed Web of Science ®Google Scholar
• Takeno M, Nagafuchi H, Kaneko S, Wakisaka S, Oneda K, Takeba Y, Yamashita N, Suzuki N, Kaneoka H, Sakane T. Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J Immunol 1997; 158:3529 - 38; PMID: 9120315
   PubMed Web of Science ®Google Scholar
• Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412 - 24; http://dx.doi.org/10.1101/gad.13.18.2412; PMID: 10500098
   PubMed Web of Science ®Google Scholar
• Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 2009; 29:1449 - 54; http://dx.doi.org/10.1007/s00296-009-0885-8; PMID: 19277666
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48:1521 - 9; http://dx.doi.org/10.1002/art.11143; PMID: 12794819
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583 - 8; http://dx.doi.org/10.1038/75068; PMID: 10802717
   PubMed Web of Science ®Google Scholar
• Burmester G, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA. Arthritis Rheum 2012; 64:S1075
   Web of Science ®Google Scholar

• Holtz J-B. oral presentation at EULAR 2013 http://www.ablynx.com/wp-content/uploads/2013/06/ALX-0061-at-EULAR-2013_beyond-TNF.pdf
   Google Scholar
• Fleischmann R, Kivitz A, Wagner F, Feinstein J, Fuhr U, Rech J, et al. A pilot study investigating the tolerability and pharmacodynamc effect of single intravenous/subcutaneous dises of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis. Arthritis and Rheumatism 2012; 64: Abstract supplement of the American College of Rheumatology/Association of Rheumatology Professionals Annual Scientific Meeting. Washington, DC November 9-14th 2012.
   Google Scholar
• Hsu B, Sheng S, Smolen J, Weinblatt M. Results from a 2-part, proof of concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis and Rheumatoid 2011; Abstract 2631, 75th Annual Meeting of ACR/ARHP, 5-9th November, Chicago.
   Google Scholar
• Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48:85 - 93; http://dx.doi.org/10.1016/j.ejca.2011.10.014; PMID: 22129890
   PubMed Web of Science ®Google Scholar
• Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71:1183 - 9; http://dx.doi.org/10.1136/annrheumdis-2011-200704; PMID: 22328739
   PubMed Web of Science ®Google Scholar
• Katzka DA, Loftus EV Jr., Camilleri M. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. Clin Pharmacol Ther 2012; 92:306 - 20; http://dx.doi.org/10.1038/clpt.2012.77; PMID: 22828717
   PubMed Web of Science ®Google Scholar
• Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23:1556 - 61; http://dx.doi.org/10.1038/nbt1166; PMID: 16299519
   PubMed Web of Science ®Google Scholar
• Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis. J Surg Res 2009; 157:235 - 42; http://dx.doi.org/10.1016/j.jss.2008.08.035; PMID: 19589542
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372:774 - 97; http://dx.doi.org/10.1016/j.jmb.2007.05.022; PMID: 17681537
   PubMed Web of Science ®Google Scholar
• Bhat TN, Bentley GA, Boulot G, Greene MI, Tello D, Dall’Acqua W, Souchon H, Schwarz FP, Mariuzza RA, Poljak RJ. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A 1994; 91:1089 - 93; http://dx.doi.org/10.1073/pnas.91.3.1089; PMID: 8302837
   PubMed Web of Science ®Google Scholar
• Lindsay MA. Target discovery. Nat Rev Drug Discov 2003; 2:831 - 8; http://dx.doi.org/10.1038/nrd1202; PMID: 14526386
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220 - 33; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x; PMID: 19459844
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol 2012; 189:4890 - 9; http://dx.doi.org/10.4049/jimmunol.1201493; PMID: 23066154
   PubMed Web of Science ®Google Scholar
• Cepica A, Yason C, Ralling G. The use of ELISA for detection of the antibody-induced conformational change in a viral protein and its intermolecular spread. J Virol Methods 1990; 28:1 - 13; http://dx.doi.org/10.1016/0166-0934(90)90082-Q; PMID: 2112149
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756 - 60; http://dx.doi.org/10.1038/nature01392; PMID: 12610629
   PubMed Web of Science ®Google Scholar
• Oyen D, Srinivasan V, Steyaert J, Barlow JN. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol 2011; 407:138 - 48; http://dx.doi.org/10.1016/j.jmb.2011.01.017; PMID: 21238460
   PubMed Web of Science ®Google Scholar
• Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 1996; 93:7843 - 8; http://dx.doi.org/10.1073/pnas.93.15.7843; PMID: 8755564
   PubMed Web of Science ®Google Scholar
• Tickle S, Adams R, Brown D, Griffiths M, Lightwood D, Lawson A. High-throughput screening for high affinity antibodies. J of Laboratory Automation 2009; 14:303 - 7; http://dx.doi.org/10.1016/j.jala.2009.05.004
   Google Scholar
• Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233:566 - 9; http://dx.doi.org/10.1126/science.3726549; PMID: 3726549
   PubMed Web of Science ®Google Scholar
• Kabat E, Wu T, Reid-Miller M, Perry H, Gottesman K. Sequences of proteins of immunological interest. US Dept of Health and Human Services, Public Health Service National Institutes of Health; 1987.
   Google Scholar
• Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130:5 - 40; http://dx.doi.org/10.1111/j.1600-065X.1992.tb01519.x; PMID: 1286872
   PubMed Web of Science ®Google Scholar
• Mason M, Sweeney B, Cain K, Stephens P, Sharfstein ST. Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells. Biotechnol Prog 2012; 28:846 - 55; http://dx.doi.org/10.1002/btpr.1542; PMID: 22467228
   PubMed Web of Science ®Google Scholar
• Leslie AG. Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 1999; 55:1696 - 702; http://dx.doi.org/10.1107/S090744499900846X; PMID: 10531519
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658 - 74; http://dx.doi.org/10.1107/S0021889807021206; PMID: 19461840
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240 - 55; http://dx.doi.org/10.1107/S0907444996012255; PMID: 15299926
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126 - 32; http://dx.doi.org/10.1107/S0907444904019158; PMID: 15572765
   PubMed Web of Science ®Google Scholar
• DeLano W. The PyMOL Molecular Graphics System. 2002; www.pymol.org
   Google Scholar
• Burmeister WP. Structural changes in a cryo-cooled protein crystal owing to radiation damage. Acta Crystallogr D Biol Crystallogr 2000; 56:328 - 41; http://dx.doi.org/10.1107/S0907444999016261; PMID: 10713520
   PubMed Web of Science ®Google Scholar
• Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010; 66:12 - 21; http://dx.doi.org/10.1107/S0907444909042073; PMID: 20057044
   PubMed Web of Science ®Google Scholar